## Case 1:16-mc-07000-WHP Document 13 Filed 02/23/17 Page 1 of 2



Christopher T. Holding 617.570.1679 CHolding@goodwinprocter.com Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210

goodwinlaw.com +1 617 570 1000

February 23, 2017

## VIA CM/ECF

Honorable William H. Pauley III United States District Judge United States District Court for the Southern District of New York Daniel Patrick Moynihan Courthouse 500 Pearl Street New York, NY 10007-1312

Re: <u>In re Topical Corticosteroid Antitrust Litigation</u>, 16-mc-7000 (Master Case Docket)

Dear Judge Pauley:

The undersigned Defendants respectfully submit this letter with respect to paragraph 21 of Your Honor's Amended Master Case Order, filed February 3, 2017, which directed the named Defendants who had not yet appeared to advise the Court by letter the counsel they wish to designate for the above-captioned master case docket.

Based upon the operative complaints at the time of the Order, this directive applied to the following four entities: Novartis International AG; Novartis AG; Sun Pharmaceutical Industries, Ltd.; and Teva Pharmaceutical Industries, Ltd. These entities were not properly served with any complaints in the consolidated and coordinated corticosteroid antitrust litigation, nor have they appeared. Pursuant to the Order, both the Direct Purchaser and End Payor Plaintiffs filed their consolidated amended complaints on February 10, 2017. Neither of those consolidated amended complaints names any of these four entities as defendants. As a result, we respectfully submit that Novartis International AG; Novartis AG; Sun Pharmaceutical Industries, Ltd.; and Teva Pharmaceutical Industries, Ltd. need not designate counsel with respect to this case and should be removed from the list of parties to these actions. <sup>1</sup>

\_

<sup>&</sup>lt;sup>1</sup> The filing of this letter should not be construed as a concession that this Court has personal jurisdiction over these entities.



Honorable William H. Pauley III February 23, 2017 Page 2

Respectfully submitted on behalf of the undersigned:

ARNOLD & PORTER KAYE SCHOLER LLP

By: /s/ Laura S. Shores Laura S. Shores 901 Fifteenth Street, NW Washington, DC 20005 Tel.: (202) 682-3577 Fax: (202) 682-3580 laura.shores@apks.com

Attorneys for Fougera Pharmaceuticals, Inc. and Sandoz, Inc.

## GOODWIN PROCTER LLP

By: /s/ Christopher T. Holding Christopher T. Holding 100 Northern Avenue Boston, MA 02210 Tel.: (617) 570-1679 Fax: (617) 523-1231

cholding@goodwinlaw.com

Attorneys for Actavis Holdco U.S., Inc. and Teva Pharmaceuticals USA, Inc.

## VENABLE LLP

By: /s/ Lisa Jose Fales 575 7th Street, NW Washington, DC 20004 Tel.: (202) 344-4000 Fax: (202) 344-8300 ljfales@venable.com

Attorneys for Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries Ltd.